COVID-19-induced neurocognitive complications that include brain fog have affected a large portion of individuals who survived COVID-19. These symptoms can include inattention, mental fatigue, forgetfulness, amotivation, and distractibility. This can cause significant anxiety and depression, which may worsen disease progression. To date, there are no known specific treatments that target COVID-19-related brain fog. Here, two patients are presented that develop symptoms of brain fog that persisted after they recovered from an acute COVID-19 infection. Both had memory impairment, mental exhaustion, and inattention with associated depressed mood. They were given bupropion extended release and though varied with dosing and time to resolution, they recovered dramatically. The dopamine and norepinephrine reuptake inhibitor is known to have effects on the brain that may treat symptoms of brain fog including blocking hippocampal cell loss, increased neural activity in the cingulate cortex, and decreasing proinflammatory cytokines. Bupropion may be a possible option for those suffering from this growing and debilitating post-COVID-19 complication.
top of page
Buscar
Posts recentes
Ver tudohttps://www.mdpi.com/1420-3049/26/8/2368#B188-molecules-26-02368 Several clinical trials attested for the antidepressant efficacy of anti-TNF-α compounds (in patients with medical illnesses, major dep
00
Intervenções para transtorno de ansiedade generalizada Byrne, Gerard J.a ,b Informação sobre o autor Academia de Psiquiatria, Faculdade de Medicina, Universidade de Queensland b Serviço de Saúde Menta
00
Review Aust N Z J Psychiatry 2013 Nov;47(11):1019-31.doi: 10.1177/0004867413491154.Epub 2013 Jun 5. Psychoeducation is a psychosocial treatment that has been well documented as an adjunct to pharmacol
20
bottom of page